SPORADIC HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

Clinical trials for SPORADIC HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS explained in plain language.

Never miss a new study

Get alerted when new SPORADIC HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS trials appear

Sign up with your email to follow new studies for SPORADIC HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New drug shows promise for rare immune disorder

Disease control Completed

This study tested the drug itacitinib in 35 adults with a mild form of hemophagocytic lymphohistiocytosis (HLH), a rare immune condition. The goal was to see if itacitinib could control the disease by day 15. Participants took the drug for at least 7 days, and researchers measure…

Matched conditions: SPORADIC HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control

Last updated Jun 16, 2026 12:52 UTC

SPORADIC HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

Get alerted when new SPORADIC HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS trials appear

New drug shows promise for rare immune disorder